EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109 · see citing works

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · see citing works

STAR: ultrafast universal RNA-seq aligner

Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709 · see citing works

<tt>edgeR</tt> : a Bioconductor package for differential expression analysis of digital gene expression data

Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364 · see citing works

Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer

Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239 · see citing works

Epigenetic Regulations of GABAergic Neurotransmission: Relevance for Neurological Disorders and Epigenetic Therapy

Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,951 · see citing works

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592 · see citing works

Triple-negative breast cancer: clinical features and patterns of recurrence

Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091 · see citing works

A Perspective on Cancer Cell Metastasis

Chaffer, C. L., & Weinberg, R. A. (2011) · Science · doi:10.1126/science.1203543 · Cited by 4,791 · see citing works

Visualizing and interpreting cancer genomics data via the Xena platform

Goldman, M. J., Craft, B., Hastie, M., Repečka, K., McDade, F., Kamath, A., Banerjee, A., Luo, Y., Rogers, D., Brooks, A. N., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0546-8 · Cited by 4,481 · see citing works

Cancer Metastasis: Building a Framework

Gupta, G. P., & Massagué, J. (2006) · Cell · doi:10.1016/j.cell.2006.11.001 · Cited by 4,328 · see citing works

The polycomb group protein EZH2 is involved in progression of prostate cancer

Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717 · see citing works

Metastatic Behavior of Breast Cancer Subtypes

Kennecke, H., Yerushalmi, R., Woods, R., Cheang, M. C. U., Voduc, D., Speers, C. H., Nielsen, T. O., & Gelmon, K. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9820 · Cited by 2,262 · see citing works

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature · doi:10.1038/nature11606 · Cited by 1,786 · see citing works

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P. L., et al. (2013) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2013-0953-sa · Cited by 1,763 · see citing works

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

Kleer, C. G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S. A., Ghosh, D., Sewalt, R. G. A. B., Otte, A. P., Hayes, D. F., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1933744100 · Cited by 1,649 · see citing works

Targeting EZH2 in cancer

Kim, K. H., & Roberts, C. W. M. (2016) · Nature Medicine · doi:10.1038/nm.4036 · Cited by 1,471 · see citing works

Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer

Burstein, M. D., Tsimelzon, A. I., Poage, G. M., Covington, K. R., Contreras, A., Fuqua, S. A. W., Savage, M. I., Osborne, C. K., Hilsenbeck, S. G., Chang, J. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0432 · Cited by 1,404 · see citing works

Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

Cheang, M. C. U., Voduc, D. K., Bajdik, C. D., Leung, S. C. Y., McKinney, S. E., Chia, S., Perou, C. M., & Nielsen, T. O. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1658 · Cited by 1,197 · see citing works

Partitioning and Plasticity of Repressive Histone Methylation States in Mammalian Chromatin

Peters, A. H. F. M., Kubicek, S., Mechtler, K., O’Sullivan, R. J., Derijck, A. A. H. A., Perez-Burgos, L., Kohlmaier, A., Opravil, S., Tachibana, M., Shinkai, Y., et al. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00477-5 · Cited by 1,148 · see citing works

Genomewide Analysis of PRC1 and PRC2 Occupancy Identifies Two Classes of Bivalent Domains

Ku, M., Koche, R. P., Rheinbay, E., Mendenhall, E. M., Endoh, M., Mikkelsen, T. S., Aiden, A. P., Nusbaum, C., Xie, X. S., Chi, A. S., et al. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000242 · Cited by 1,053 · see citing works

Ezh1 and Ezh2 Maintain Repressive Chromatin through Different Mechanisms

Margueron, R., Li, G., Sarma, K., Blais, A., Zavadil, J., Woodcock, C. L. F., Dynlacht, B. D., & Reinberg, D. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.11.004 · Cited by 889 · see citing works

Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs

Oskarsson, T., Acharyya, S., Zhang, X. H.-F., Vanharanta, S., Tavazoie, S. F., Morris, P. G., Downey, R. J., Manova-Todorova, K., Brogi, E., & Massagué, J. (2011) · Nature Medicine · doi:10.1038/nm.2379 · Cited by 869 · see citing works

Polycomb silencing mechanisms and the management of genomic programmes

Schwartz, Y. B., & Pirrotta, V. (2007) · Nature Reviews Genetics · doi:10.1038/nrg1981 · Cited by 868 · see citing works

Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer

van Haaften, G., Dalgliesh, G. L., Davies, H., Chen, L., Bignell, G., Greenman, C., Edkins, S., Hardy, C., O'Meara, S., Teague, J., et al. (2009) · Nature Genetics · doi:10.1038/ng.349 · Cited by 784 · see citing works

Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters

Cheung, K. J., Padmanaban, V., Silvestri, V. L., Schipper, K., Cohen, J. D., Fairchild, A. N., Gorin, M. A., Verdone, J. E., Pienta, K. J., Bader, J. S., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1508541113 · Cited by 737 · see citing works

Differential chromatin marking of introns and expressed exons by H3K36me3

Kolasinska-Zwierz, P., Down, T. A., Latorre, I. J., Liu, T., Liu, X. S., & Ahringer, J. (2009) · Nature Genetics · doi:10.1038/ng.322 · Cited by 695 · see citing works

Sp1‐mediated transcriptional activation is repressed by Sp3.

Hagen, G., Müller, S., Beato, M., & Suske, G. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06695.x · Cited by 685 · see citing works

Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors

Gurney, A., Axelrod, F., Bond, C. J., Cain, J., Chartier, C., Donigan, L., Fischer, M., Chaudhari, A., Ji, M., Kapoun, A. M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120068109 · Cited by 614 · see citing works

Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer

Hon, G. C., Hawkins, R. D., Caballero, O. L., Lo, C., Lister, R., Pelizzola, M., Valsesia, A., Ye, Z., Kuan, S., Edsall, L. E., et al. (2012) · Genome Research · doi:10.1101/gr.125872.111 · Cited by 583 · see citing works

Keratins in health and cancer: more than mere epithelial cell markers

Karantza, V. (2010) · Oncogene · doi:10.1038/onc.2010.456 · Cited by 560 · see citing works

H3K4me3 breadth is linked to cell identity and transcriptional consistency

Benayoun, B. A., Pollina, E. A., Ucar, D., Mahmoudi, S., Karra, K., Wong, E. D., Devarajan, K., Daugherty, A. C., Kundaje, A. B., Mancini, E., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.027 · Cited by 536 · see citing works

Epigenomic reprogramming during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis

McDonald, O. G., Li, X., Saunders, T., Tryggvadottir, R., Mentch, S. J., Warmoes, M. O., Word, A. E., Carrer, A., Salz, T. H., Natsume, S., et al. (2017) · Nature Genetics · doi:10.1038/ng.3753 · Cited by 494 · see citing works

Tazemetostat: First Approval

Hoy, S. M. (2020) · Drugs · doi:10.1007/s40265-020-01288-x · Cited by 340 · see citing works

Preclinical mouse solid tumour models: status quo, challenges and perspectives

Gengenbacher, N., Singhal, M., & Augustin, H. G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.92 · Cited by 332 · see citing works

ChIP-seq analysis reveals distinct H3K27me3 profiles that correlate with transcriptional activity

Young, M. D., Willson, T. A., Wakefield, M. J., Trounson, E., Hilton, D. J., Blewitt, M. E., Oshlack, A., & Majewski, I. J. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr416 · Cited by 312 · see citing works

Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator

Kim, J., Lee, Y., Lü, X., Song, B., Fong, K.-W., Cao, Q., Licht, J. D., Zhao, J. C., & Yu, J. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.035 · Cited by 308 · see citing works

ID genes mediate tumor reinitiation during breast cancer lung metastasis

Gupta, G. P., Perk, J., Acharyya, S., de Candia, P., Mittal, V., Manova-Todorova, K., Gerald, W. L., Brogi, E., Benezra, R., & Massagué, J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709185104 · Cited by 242 · see citing works

Pemigatinib: First Approval

Hoy, S. M. (2020) · Drugs · doi:10.1007/s40265-020-01330-y · Cited by 242 · see citing works

Discovery of a first-in-class EZH2 selective degrader

Ma, A., Στρατικόπουλος, Η., Park, K., Wei, J., Martin, T. C., Yang, X., Schwarz, M. C., Leshchenko, V. V., Rialdi, A., Dale, B., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0421-4 · Cited by 240 · see citing works

Splenic Metastases: Clinicopathologic Presentation, Differential Diagnosis, and Pathogenesis

Compérat, É., Bardier–Dupas, A., Camparo, P., Capron, F., & Charlotte, F. (2007) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2007-131-965-smcpdd · Cited by 231 · see citing works

Sonic Hedgehog Signaling in Organogenesis, Tumors, and Tumor Microenvironments

Jeng, K., Chang, C., & Lin, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030758 · Cited by 208 · see citing works

Enhancer of zeste homolog 2 (EZH2) inhibitors

Gulati, N., Béguelin, W., & Giulino-Roth, L. G. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1430795 · Cited by 196 · see citing works

EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis

Wang, J., Yu, X., Gong, W., Liu, X., Park, K., Ma, A., Tsai, Y., Shen, Y., Onikubo, T., Pi, W., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00850-x · Cited by 187 · see citing works

EZH2 expands breast stem cells through activation of NOTCH1 signaling

Gonzalez, M. E., Moore, H. M., Li, X., Toy, K. A., Huang, W., Sabel, M. S., Kidwell, K., & Kleer, C. G. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1308953111 · Cited by 185 · see citing works

Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition

Hohmann, A. F., Martin, L. J., Minder, J. L., Roe, J., Shi, J., Steurer, S., Bader, G., McConnell, D. B., Pearson, M. A., Gerstberger, T., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2115 · Cited by 184 · see citing works

EZH2 engages TGFβ signaling to promote breast cancer bone metastasis via integrin β1-FAK activation

Zhang, L., Qu, J., Qi, Y., Duan, Y., Huang, Y.-W., Zhou, Z., Li, P., Yao, J., Huang, B., Zhang, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30105-0 · Cited by 182 · see citing works

Hyperconserved CpG domains underlie Polycomb-binding sites

Tanay, A., O’Donnell‐Luria, A., Damelin, M. I., & Bestor, T. H. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609746104 · Cited by 176 · see citing works

KRT14 marks a subpopulation of bladder basal cells with pivotal role in regeneration and tumorigenesis

Papafotiou, G., Paraskevopoulou, V., Vasilaki, E., Kanaki, Z., Paschalidis, N., & Klinakis, A. (2016) · Nature Communications · doi:10.1038/ncomms11914 · Cited by 173 · see citing works

ATF3, an adaptive-response gene, enhances TGFβ signaling and cancer-initiating cell features in breast cancer cells

Yin, X. H., Wolford, C. C., Chang, Y.-S., McConoughey, S. J., Ramsey, S. A., Aderem, A. A., & Hai, T. (2010) · Journal of Cell Science · doi:10.1242/jcs.064915 · Cited by 163 · see citing works

Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes

Holm, K., Grabau, D. A., Lövgren, K., Aradottir, S., Gruvberger-Saal, S. K., Howlin, J., Saal, L. H., Ethier, S. P., Bendahl, P., Stål, O., et al. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.06.002 · Cited by 161 · see citing works

Changes in Keratin Expression during Metastatic Progression of Breast Cancer: Impact on the Detection of Circulating Tumor Cells

Joosse, S. A., Hannemann, J., Spötter, J., Bauche, A., Andreas, A., Müller, V., & Pantel, K. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2100 · Cited by 155 · see citing works

A unique H3K4me2 profile marks tissue-specific gene regulationPreprint

Pękowska, A., Benoukraf, T., Ferrier, P., & Spicuglia, S. (2010) · Genome Research · doi:10.1101/gr.109389.110 · Cited by 149 · see citing works

Quantitative Mass Spectrometry of Histones H3.2 and H3.3 in Suz12-deficient Mouse Embryonic Stem Cells Reveals Distinct, Dynamic Post-translational Modifications at Lys-27 and Lys-36

Jung, H. R., Pasini, D., Helin, K., & Jensen, O. N. (2010) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m900489-mcp200 · Cited by 136 · see citing works

p38-mediated phosphorylation at T367 induces EZH2 cytoplasmic localization to promote breast cancer metastasis

Anwar, T., Arellano-Garcia, C., Ropa, J. P., Chen, Y., Kim, H. S., Yoon, E., Grigsby, S. M., Basrur, V., Nesvizhskii, A. I., Muntean, A. G., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05078-8 · Cited by 117 · see citing works

Blocking immunosuppressive neutrophils deters pY696-EZH2–driven brain metastases

Zhang, L., Yao, J., Wei, Y., Zhou, Z., Li, P., Qu, J., Badu-Nkansah, A., Yuan, X., Huang, Y.-W., Fukumura, K., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz5387 · Cited by 113 · see citing works

Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer

Yomtoubian, S., Lee, S. B., Verma, A., Izzo, F., Markowitz, G. J., Choi, H., Cerchietti, L. C. A., Vahdat, L. T., Brown, K. A., Andreopoulou, E., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2019.12.056 · Cited by 111 · see citing works

IRF9 and unphosphorylated STAT2 cooperate with NF-κB to drive IL6 expression

Jing, N., Wang, Y., Yang, J. B., & Stark, G. R. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1714102115 · Cited by 109 · see citing works

Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer

Lui, V. W. Y., Peyser, N. D., Ng, P. K., Hritz, J., Zeng, Y., Lu, Y., Li, H., Wang, L., Gilbert, B. R., General, I. J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319551111 · Cited by 102 · see citing works

Peritoneal metastases from extra-abdominal cancer – A population-based study

Flanagan, M. P., Solon, J. G., Chang, K. H., Deady, S., Moran, B., Cahill, R. A., Shields, C. J., & Mulsow, J. (2018) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2018.07.049 · Cited by 88 · see citing works

Id2 Promotes Tumor Cell Migration and Invasion through Transcriptional Repression of Semaphorin 3F

Coma, S., Amin, D. N., Shimizu, A., Lasorella, A., Iavarone, A., & Klagsbrun, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3048 · Cited by 88 · see citing works

p53 is a NF‐Y‐ and p21‐independent, Sp1‐dependent repressor of cyclin B1 transcription

Innocente, S. A., & Lee, J. M. (2005) · FEBS Letters · doi:10.1016/j.febslet.2004.12.073 · Cited by 87 · see citing works

Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program

Hirukawa, A., Smith, H. W., Zuo, D., Dufour, C. R., Savage, P., Bertos, N., Johnson, R. M., Bui, T., Bourque, G., Basik, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04864-8 · Cited by 82 · see citing works

Epigenetic Therapy for Epithelioid Sarcoma

Rothbart, S. B., & Baylin, S. B. (2020) · Cell · doi:10.1016/j.cell.2020.03.042 · Cited by 76 · see citing works

A partially disordered region connects gene repression and activation functions of EZH2

Jiao, L., Shubbar, M., Yang, X., Zhang, Q., Chen, S., Wu, Q., Chen, Z., Rizo, J., & Liu, X. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1914866117 · Cited by 59 · see citing works

Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer

Hussein, Y. R., Sood, A. K., Bandyopadhyay, S., Albashiti, B., Semaan, A. Y., Nahleh, Z. A., Roh, J., Han, H. D., Lopez‐Berestein, G., & Ali‐Fehmi, R. (2012) · Human Pathology · doi:10.1016/j.humpath.2011.12.004 · Cited by 58 · see citing works

Prevalence, risk factors, and prognosis of peritoneal metastasis from breast cancer

Bertozzi, S., Londero, A. P., Cedolini, C., Uzzau, A., Seriau, L., Bernardi, S., Bacchetti, S., Pasqual, E. M., & Risaliti, A. (2015) · SpringerPlus · doi:10.1186/s40064-015-1449-x · Cited by 56 · see citing works

EZH2 inhibition decreases p38 signaling and suppresses breast cancer motility and metastasis

Moore, H. M., Gonzalez, M. E., Toy, K. A., Cimino‐Mathews, A., Argani, P., & Kleer, C. G. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2498-x · Cited by 52 · see citing works

CXCR4 intracellular protein promotes drug resistance and tumorigenic potential by inversely regulating the expression of Death Receptor 5

Nengroo, M. A., Maheshwari, S., Singh, A., Verma, A., Arya, R. K., Chaturvedi, P., Saini, K. K., Singh, A. K., Sinha, A., Meena, S., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03730-8 · Cited by 51 · see citing works

EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features

Guo, S., Li, X., Rohr, J. M., Wang, Y., Ma, S., Chen, P., & Wang, Z. (2016) · Diagnostic Pathology · doi:10.1186/s13000-016-0491-5 · Cited by 48 · see citing works

Novel Model for Basaloid Triple-negative Breast Cancer: Behavior In Vivo and Response to Therapy

Volk-Draper, L. D., Rajput, S., Hall, K. L., Wilber, A. C., & Rana, S. (2012) · Neoplasia · doi:10.1593/neo.12956 · Cited by 44 · see citing works

Regulation of Cellular Heterogeneity and Rates of Symmetric and Asymmetric Divisions in Triple-Negative Breast Cancer

Granit, R. Z., Masury, H., Condiotti, R., Fixler, Y., Gabai, Y., Glikman, T., Dalin, S., Winter, E. E., Nevo, Y., Carmon, E., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.08.053 · Cited by 44 · see citing works

Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer

Seachrist, D. D., Sizemore, S. T., Johnson, E., Abdul‐Karim, F. W., Weber-Bonk, K. L., & Keri, R. A. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0857-y · Cited by 41 · see citing works

EZH2 promotes a bi-lineage identity in basal-like breast cancer cells

Granit, R. Z., Gabai, Y., Hadar, T., Karamansha, Y., Liberman, L., Waldhorn, I., Gat‐Viks, I., Regev, A., Maly, B., Darash‐Yahana, M., et al. (2012) · Oncogene · doi:10.1038/onc.2012.390 · Cited by 38 · see citing works

The Epigenetic Landscape of Promoter Genome-wide Analysis in Breast Cancer

Karslı-Çeppioğlu, S., Dagdemir, A., Judes, G., Lebert, A., Penault-Llorca, F. M., Bignon, Y., & Bernard-Gallon, D. J. (2017) · Scientific Reports · doi:10.1038/s41598-017-06790-z · Cited by 36 · see citing works

Peritoneal Metastases from Breast Cancer: A Scoping Review

Beniey, M. (2019) · Cureus · doi:10.7759/cureus.5367 · Cited by 35 · see citing works

Treating lymphoma is now a bit EZ-er

Morin, R. D., Arthur, S. E., & Assouline, S. E. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020002773 · Cited by 32 · see citing works

p53 Acts as a Co-Repressor to Regulate Keratin 14 Expression during Epidermal Cell Differentiation

Cai, B., Hsu, P.-C., Hsin, I., Chao, C., Lu, M., Lin, H.-C., Chiou, S., Tao, P., & Chen, J.-Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041742 · Cited by 31 · see citing works

Salinomycin inhibits epigenetic modulator EZH2 to enhance death receptors in colon cancer stem cells

Singh, A. K., Verma, A., Singh, A., Arya, R. K., Maheshwari, S., Chaturvedi, P., Nengroo, M. A., Saini, K. K., Vishwakarma, A. L., Singh, K., et al. (2020) · Epigenetics · doi:10.1080/15592294.2020.1789270 · Cited by 29 · see citing works

Heterogeneity at the invasion front of triple negative breast cancer cells

Yong, K. M. A., Ulintz, P., Cáceres, S., Cheng, X., Bao, L., Wu, Z., Jiagge, E. M., & Merajver, S. D. (2020) · Scientific Reports · doi:10.1038/s41598-020-62516-8 · Cited by 27 · see citing works

Discovery of a Novel Small-Molecule Inhibitor that Targets PP2A–β-Catenin Signaling and Restricts Tumor Growth and Metastasis

Maheshwari, S., Avula, S. R., Singh, A., Singh, L., Palnati, G. R., Arya, R. K., Cheruvu, H. S., Shahi, S., Sharma, T., Meena, S., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0584 · Cited by 22 · see citing works

Salinomycin inhibits epigenetic modulator EZH2 to enhance Death Receptors in Colon Cancer Stem CellsPreprint

Singh, A. K., Verma, A., Singh, A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.03.932269 · Cited by 11 · see citing works

Abstract 3837: Selective ezh2 functional activation alters the metastatic landscape of triple negative breast cancer

Verma, A., Singh, A., Singh, A. K., Chaturvedi, P., Nengroo, M. A., Saini, K. K., Sinha, A., & Datta, D. B. (2020) · Cancer Research · doi:10.1158/1538-7445.am2020-3837 · Cited by 1 · see citing works

Circulating tumor cells: from new biological insights to clinical practice

Gu, X., Wei, S., & Lv, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01938-6 · Cited by 204 · see citing works

Epigenetic regulation in cancer

Gu, M., Ren, B., Fang, Y., Ren, J., Liu, X., Wang, X., Zhou, F., Xiao, R., Luo, X., You, L., et al. (2024) · MedComm · doi:10.1002/mco2.495 · Cited by 119 · see citing works

Aspects of the Epigenetic Regulation of EMT Related to Cancer Metastasis

Nowak, E., & Bednarek, I. A. (2021) · Cells · doi:10.3390/cells10123435 · Cited by 110 · see citing works

Epigenetic regulators in cancer therapy and progression

Marei, H. E. S. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01003-7 · Cited by 101 · see citing works

Epigenetic regulation in cancer therapy: From mechanisms to clinical advances

Tao, L., Zhou, Y., Luo, Y., Qiu, J., Xiao, Y., Zou, J., Zhang, Y., Liu, X., Yang, X., Gou, K., et al. (2024) · MedComm – Oncology · doi:10.1002/mog2.59 · Cited by 93 · see citing works

Loss of PERK function promotes ferroptosis by downregulating SLC7A11 (System Xc⁻) in colorectal cancer

Saini, K. K., Chaturvedi, P., Sinha, A., Singh, M. P., Khan, M. A., Verma, A., Nengroo, M. A., Satrusal, S. R., Meena, S., Singh, A., et al. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102833 · Cited by 82 · see citing works

Molecular profile of metastasis, cell plasticity and EMT in pancreatic cancer: a pre-clinical connection to aggressiveness and drug resistance

Guo, Z., Ashrafizadeh, M., Zhang, W., Zou, R., Sethi, G., & Zhang, X. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10125-y · Cited by 63 · see citing works

Ferroptosis-enhanced chemotherapy for triple-negative breast cancer with magnetic composite nanoparticles

Zhang, J., Zhou, K., Lin, J., Yao, X., Ju, D., Zeng, X. L., Pang, Z., & Yang, W. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122395 · Cited by 55 · see citing works

Regulation of EZH2 protein stability: new mechanisms, roles in tumorigenesis, and roads to the clinic

Guo, Y., Cheng, R., Wang, Y., Gonzalez, M. E., Zhang, H., Liu, Y., Kleer, C. G., & Xue, L. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.104972 · Cited by 55 · see citing works

TRIM21-mediated Sohlh2 ubiquitination suppresses M2 macrophage polarization and progression of triple-negative breast cancer

Zhang, R., Shen, Y., Zhang, Q., Feng, X., Liu, X., Huo, X., Sun, J., & Hao, J. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06383-x · Cited by 53 · see citing works

Enhancer reprogramming: critical roles in cancer and promising therapeutic strategies

Yang, J., Zhou, F., Luo, X., Fang, Y., Wang, X., Liu, X., Xiao, R., Jiang, D., Tang, Y., Yang, G., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02366-3 · Cited by 50 · see citing works

Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies

Zhou, K., Liu, X., & Zhu, H. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01752-9 · Cited by 49 · see citing works

Targeted deprivation of methionine with engineered Salmonella leads to oncolysis and suppression of metastasis in broad types of animal tumor models

Zhou, S., Lin, Y., Zhao, Z., Lai, Y., Lü, M., Shao, Z., Mo, X., Mu, Y., Liang, Z., Wang, X., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101070 · Cited by 40 · see citing works

NOP2 facilitates EZH2-mediated epithelial–mesenchymal transition by enhancing EZH2 mRNA stability via m5C methylation in lung cancer progression

Yang, Y., Fan, H., Lou, X., Lou, X., Xiao, N., Zhang, C., Chen, S., Chen, S., Liu, H., Liu, H., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06899-w · Cited by 37 · see citing works

ACSL4-mediated H3K9 and H3K27 hyperacetylation upregulates SNAIL to drive TNBC metastasis

Sinha, A., Saini, K. K., Chandramouli, A., Tripathi, K., Khan, M. A., Satrusal, S. R., Verma, A., Mandal, B., Rai, P., Meena, S., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2408049121 · Cited by 27 · see citing works

Dual target PARP1/EZH2 inhibitors inducing excessive autophagy and producing synthetic lethality for triple-negative breast cancer therapy

Li, X., Wang, C., Li, S., Yin, F., Luo, H., Zhang, Y., Luo, Z., Chen, Y., Wan, S., Kong, L., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116054 · Cited by 26 · see citing works

Caffeic acid inhibits the tumorigenicity of triple-negative breast cancer cells through the FOXO1/FIS pathway

Xie, C., Chan, L., Pang, Y., Shang, Y., Cao, W., Tuohan, M., Deng, Q., Wang, Y., Zhao, L., & Wang, W. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117158 · Cited by 26 · see citing works

A Kaleidoscope of Keratin Gene Expression and the Mosaic of Its Regulatory Mechanisms

Kalabusheva, E., Shtompel, A. S., Rippa, A., Ulianov, S., Razin, S., & Vorotelyak, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065603 · Cited by 22 · see citing works

Nanoparticle drug delivery systems responsive to tumor microenvironment: Promising alternatives in the treatment of triple‐negative breast cancer

Cao, Y., Meng, F., Cai, T., Gao, L., Lee, J., Solomevich, S. O., Aharodnikau, U. E., Guo, T., Lan, M., Liu, F., et al. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1950 · Cited by 23 · see citing works

Regulation of histone H3K27 methylation in inflammation and cancer

Ma, J., Zhang, Y., Li, J., Dang, Y., & Hu, D. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00254-x · Cited by 26 · see citing works

Hydrophobic tagging of small molecules: an overview of the literature and future outlook

Zhou, Y., Zhou, F., Xu, S., Shi, D., Ding, D., Wang, S., Poongavanam, V., Tang, K., Liu, X., & Zhan, P. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2360416 · Cited by 20 · see citing works

PRMT6 facilitates EZH2 protein stability by inhibiting TRAF6-mediated ubiquitination degradation to promote glioblastoma cell invasion and migration

Wang, J., Shen, S., You, J., Wang, Z., Li, Y., Chen, Y., Tuo, Y., Chen, D., Yu, H., Zhang, J., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06920-2 · Cited by 19 · see citing works

Targeting polycomb repressor complex 2‐mediated bivalent promoter epigenetic silencing of secreted frizzled‐related protein 1 inhibits cholangiocarcinoma progression

Wu, G., Wang, Q., Wang, D., Xiong, F., Liu, W., Chen, J., Wang, B., Huang, W., Wang, X., & Chen, Y. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1502 · Cited by 18 · see citing works

Downregulation of MLF1 safeguards cardiomyocytes against senescence-associated chromatin opening

Lv, J., Chen, Q., Wang, J., Guo, N., Yu, F., Guo, Q., Li, J., Ma, X., Zhan, H., Chen, W., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae1176 · Cited by 16 · see citing works

MT1G induces lipid droplet accumulation through modulation of H3K14 trimethylation accelerating clear cell renal cell carcinoma progression

Wang, S., Wang, K., Yue, D., Yang, X., Pan, X., Kong, F., Zhao, R., Bie, Q., Tian, D., Zhu, S., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02747-y · Cited by 15 · see citing works

Epigenetic regulation of reprogramming and pluripotency: insights from histone modifications and their implications for cancer stem cell therapies

Bae, W., Ra, E. A., & Lee, M. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1559183 · Cited by 17 · see citing works

A targetable antioxidant defense mechanism to EZH2 inhibitors enhances tumor cell vulnerability to ferroptosis

Nocito, M. C., Hantel, C., Lerário, A. M., Mastrorocco, F., Martino, L. D., Musicco, C., Perrotta, I. D., Scalise, M., Indiveri, C., Giannattasio, S., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07607-y · Cited by 14 · see citing works

Multi-omics analysis of the tumor microenvironment after metastasis: advancing toward personalized immunotherapy and molecular targeted strategies

Gao, Q., Wu, H., Duan, L., Lv, G., & Quan, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1648987 · Cited by 14 · see citing works

Biological Basis of Breast Cancer-Related Disparities in Precision Oncology Era

Neagu, A.-N., Bruno, P. S., Johnson, K. R., Ballestas, G., & Darie, C. C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25074113 · Cited by 14 · see citing works

A multi-mode Rhein-based nano-platform synergizing ferrotherapy/chemotherapy-induced immunotherapy for enhanced tumor therapy

Zhu, X., Xie, L., Tian, J., Jiang, Y., Song, E., & Song, Y. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.03.030 · Cited by 13 · see citing works

RBM15-Mediated N6-Methyl Adenosine (m6A) Modification of EZH2 Drives the Epithelial-Mesenchymal Transition of Cervical Cancer

Wang, R., & Tan, W. (2024) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukaryotgeneexpr.2024052205 · Cited by 12 · see citing works

Dual-target EZH2 inhibitor: latest advances in medicinal chemistry

Wei, L., Mei, D., Hu, S., & Du, S. (2024) · Future Medicinal Chemistry · doi:10.1080/17568919.2024.2380243 · Cited by 13 · see citing works

Pancreatic ductal adenocarcinoma cells reshape the immune microenvironment: Molecular mechanisms and therapeutic targets

Zhao, Y., Qin, C., Chen, L., Li, Z., Zhao, B., Li, T., Zhang, X., & Wang, W. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189183 · Cited by 13 · see citing works

Targeting EZH2 regulates the biological characteristics of glioma stem cells via the Notch1 pathway

Zhao, G., Deng, Z., Li, X., Wang, H., Chen, G., Feng, M., & Zhou, Y. (2023) · Experimental Brain Research · doi:10.1007/s00221-023-06693-8 · Cited by 11 · see citing works

EZH2-mediated suppression of TIMP1 in spinal GABAergic interneurons drives microglial activation via MMP-9-TLR2/4-NLRP3 signaling in neuropathic pain

Wan, L., Guo, H., Hu, F., Pan, Y., Yang, S., Jiang, C., Liu, W., Wu, X., & Wu, X. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.04.007 · Cited by 13 · see citing works

Clinical Progress of Targeted Therapy for Breast Cancer: A Comprehensive Review

Debnath, A., & Mazumder, R. (2024) · Current Cancer Drug Targets · doi:10.2174/0115680096289260240311062343 · Cited by 11 · see citing works

Advances in prognostic models for osteosarcoma risk

Yao, Y., Wang, D., Li, Z., Zhao, J., & Tan, M. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28493 · Cited by 11 · see citing works

Oncolytic adenovirus encoding apolipoprotein A1 suppresses metastasis of triple-negative breast cancer in mice

Dong, J., Kong, L., Wang, S., Mao, X., Zhang, Y., Wu, J., Yang, F., Zuo, S., & Wei, J. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03011-0 · Cited by 11 · see citing works

Reticulophagy promotes EMT-induced fibrosis in offspring’s lung tissue after maternal exposure to carbon black nanoparticles during gestation by a m5C-dependent manner

Du, Z., Liu, Q., Wang, M., Gao, Y., Li, Q., Yang, Y., Lu, T., Bao, L., Pang, Y., Wang, H., et al. (2024) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2024.136873 · Cited by 10 · see citing works

Organoid technologies in antitumor drug screening: past development, present applications, and future prospects

Yang, J., Yang, Y., Xu, P., Yao, Y., Tian, H., Wang, X., Fang, H., Ge, S., Yao, Y., Wang, Y., et al. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002530 · Cited by 10 · see citing works

H3K27me3 of Rnf19a promotes neuroinflammatory response during Japanese encephalitis virus infection

Zhu, S., Tao, M., Li, Y., Wang, X., Zhao, Z., Liu, Y., Li, Q., Li, Q., Lu, Y., Si, Y., et al. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02852-4 · Cited by 9 · see citing works

The prognostic marker KRT81 is involved in suppressing CD8 + T cells and predicts immunotherapy response for triple-negative breast cancer

Yan, Z., Zhong, Z., Shi, C., Feng, M., Feng, X., & Liu, T. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2355705 · Cited by 9 · see citing works

Research trends on nanomaterials in triple negative breast cancer (TNBC): a bibliometric analysis from 2010 to 2024

Liang, H., Yin, G., Feng, D., Chen, H., Liu, X., & Li, J. (2024) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01704-9 · Cited by 9 · see citing works

Epigenetic Modulation and Bone Metastasis: Evolving Therapeutic Strategies

Zhra, M., Holail, J., & Mohammad, K. S. (2025) · Pharmaceuticals · doi:10.3390/ph18081140 · Cited by 8 · see citing works

In situ multi-modal characterization of pancreatic cancer reveals tumor cell identity as a defining factor of the surrounding microenvironment

Lyubetskaya, A., Rabe, B. A., Kavran, A. J., Bai, Y., Fisher, A., Font‐Tello, A., Lewin, A. C., Pliner, H. A., Fan, Y., Giampapa, L., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2025.116827 · Cited by 8 · see citing works

Research progress on the regulatory mechanisms of FOXC1 expression in cancers and its role in drug resistance

Yang, Y., Li, W., Yang, H., Zhang, Y., Zhang, S., Xu, F., Yue, H., Cao, W., Du, G., & Wang, J. (2023) · Gene · doi:10.1016/j.gene.2023.148079 · Cited by 7 · see citing works

Corynoxine exerts the anti-tumor effect on esophageal squamous cell carcinoma principally via the EZH2-DUSP5-ERK1/2-mediated cell growth inhibition

Huang, G., Xu, J., Li, Y., Song, L., Wen, C., Ruan, Q., Wen, Z., Qi, J., Deng, J., & Liu, Y. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156103 · Cited by 7 · see citing works

Enhancing curcumol delivery through PD-1 targeted nanocarriers: A novel therapeutic approach for prostate cancer

Zhang, H., Du, Y., Liu, X., Gao, R., Xu, X., Hou, X., Liu, Z., Xin, P., Wu, W., Liu, T., et al. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156595 · Cited by 7 · see citing works

LncRNA-MALAT1 promotes triple-negative breast cancer progression and function as ceRNA to target REEP5 by sponging miR-106a-5p

Yang, Q.-H., Fu, Y., Feng, W., Mao, J.-F., Xu, N., Liu, Q., Yan, Q.-J., Yang, H., & Zhang, X. (2025) · European journal of medical research · doi:10.1186/s40001-025-02420-x · Cited by 7 · see citing works

Inhibition of the Sp1/PI3K/AKT signaling pathway exacerbates doxorubicin-induced cardiomyopathy

Xiang, G., Shi, T., Nwaele, C. O., Xiao, H., Liu, Y., Wang, Q., Zhang, J., & Zheng, Y. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2025.119960 · Cited by 7 · see citing works

EZH2 loss promotes gastric squamous cell carcinoma

Zhang, M., Zhong, A., Liu, H., Zhao, L., Wang, Y. F., Lu, Z., Zhang, L., Pan, X., Liang, Z., Gao, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61024-5 · Cited by 6 · see citing works

An overview of recent advancements in targeted cancer therapies and their potential clinical impact

Ahmed, S., Sakla, A. P., Jahan, K., Neshat, N., Akhter, M., Aaghaz, S., & Kamal, A. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00740b · Cited by 6 · see citing works

Emerging role of EZH2 in solid tumor metastasis

Verma, A., Khan, M. A., Satrusal, S. R., & Datta, D. B. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189253 · Cited by 6 · see citing works

Identification of key genes linking bisphenols exposure and breast cancer

Wang, Z., Cao, M., Gao, T., Xu, X., Yu, W., Liu, J., Liu, R., Zhang, X., Li, F., & Hai, C. (2025) · Toxicology · doi:10.1016/j.tox.2025.154123 · Cited by 6 · see citing works

Identifying the effectiveness of 3D culture systems to recapitulate breast tumor tissue in situ

Ludwik, K. A., Greathouse, F. R., Han, S. S., Stauffer, K. M., Brenin, D. R., Stricker, T. P., & Lannigan, D. A. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00877-8 · Cited by 5 · see citing works

Glucocorticoid receptor: a harmonizer of cellular plasticity in breast cancer—directs the road towards therapy resistance, metastatic progression and recurrence

Thakur, D., Sengupta, D., Mahapatra, E., Das, S., Sarkar, R., & Mukherjee, S. (2024) · Cancer Metastasis Review · doi:10.1007/s10555-023-10163-6 · Cited by 5 · see citing works

PALB2-mutated human mammary cells display a broad spectrum of morphological and functional abnormalities induced by increased TGFβ signaling

Tuppurainen, H., Laurila, N., Nätynki, M., Eshraghi, L., Tervasmäki, A., Erichsen, L., Sørensen, C. S., Pylkäs, K., Winqvist, R., & Peltoketo, H. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05183-6 · Cited by 5 · see citing works

Histone modifications and depression: epigenetic mechanisms, therapeutic targets, and translational outlook

Lv, L.-Z., Wang, Z.-D., Ren, J.-J., Li, L.-H., Liu, X.-B., Li, J.-L., Zhu, H., Jiang, B., Han, Y.-P., Zhou, X.-M., et al. (2026) · Frontiers in Genetics · doi:10.3389/fgene.2025.1722453 · Cited by 7 · see citing works

Quantitative Pattern of hPTMs by Mass Spectrometry-Based Proteomics with Implications for Triple-Negative Breast Cancer

Liu, C., Xu, M., Wan, L., Cao, X., Wang, Y., Chen, H., Zhang, T., Lu, M., Xie, H., & Chen, Y. (2024) · Journal of Proteome Research · doi:10.1021/acs.jproteome.4c00034 · Cited by 4 · see citing works

Deciphering progressive lesion areas in breast cancer spatial transcriptomics via TGR-NMF

Li, J., Shan, X., & Wei, D. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae707 · Cited by 4 · see citing works

Dapagliflozin ameliorates high glucose-induced epithelial-mesenchymal transition via up-regulating ACE2 mediated by EZH2 in diabetic nephropathy

Wang, S., Zhang, X., Chong, N., Chen, D., Shu, J., Wang, R., Wang, Q., & Xu, Y. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02650-0 · Cited by 4 · see citing works

Whole-transcriptome sequencing analysis of spinal neuronal ferroptosis in aggravating neuropathic pain

Gao, X., Liang, X., Gao, L., Zhang, Y., Zhang, L., Jia, S., Zhang, B., & Meng, C. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123882 · Cited by 4 · see citing works

Ellagic acid inhibits EZH2: a potential epigenetic therapeutic molecule for cancer

Nalla, K., Chatterjee, B., Poyya, J., Swain, A., Ghosh, K., Pan, A., Joshi, C. G., Manavathi, B., & Kanade, S. R. (2025) · Cancer Genetics · doi:10.1016/j.cancergen.2025.09.001 · Cited by 4 · see citing works

Neuroinflammation and blood–brain barrier disruption in Japanese encephalitis virus infection: mechanisms, therapeutic targets, and intervention strategies

Ye, X., Wang, P., Song, M., Zhang, J., Li, X., & Wang, X. (2026) · Archives of Pharmacal Research · doi:10.1007/s12272-026-01598-w · Cited by 4 · see citing works

ZNF468-mediated epigenetic upregulation of VEGF-C facilitates lymphangiogenesis and lymphatic metastasis in ESCC via PI3K/Akt and ERK1/2 signaling pathways

Zhu, J., Qiu, X., Jin, X., Nie, X., Ou, S., Wu, G., Shen, J., & Zhang, R. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00976-0 · Cited by 4 · see citing works

Enhancer zeste homolog 2 (EZH2) targeting by small interfering RNA (siRNA); recent advances and prospect

Hsu, C., Mohammed, A. N., Hjazi, A. M., Uthirapathy, S., RenukaJyothi, S., Singh, A., Thyagarajan, Ray, S., & Hulail, H. M. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-03883-9 · Cited by 4 · see citing works

A previously uncharacterized role of TAp73 in ferroptosis by modulating oxidative homeostasis in cervical cancer

Gong, Y., Zhang, W., Wang, X., Zheng, S., Liu, H., Lin, Q., Wang, M., Ma, J., Zhang, Y., Li, T., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217815 · Cited by 4 · see citing works

Tumor-Intrinsic Enhancer of Zeste Homolog 2 Controls Immune Cell Infiltration, Tumor Growth, and Lung Metastasis in a Triple-Negative Breast Cancer Model

Monterroza, L., Parrilla, M. M., Samaranayake, S. G., Rivera-Rodriguez, D. E., Yoon, S. B., Bommireddy, R., Hosten, J., Barragan, L. C., Marcus, A. I., Dobosh, B. S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105392 · Cited by 4 · see citing works

SETD7-mediated H3K4me1 activates ALDH1A3 to drive ferroptosis resistance in esophageal squamous cell carcinoma

Feng, Y., Liu, X., Wang, Y., Zhang, M., Ji, Y., Zhang, L., Tong, Y., Zhou, F., Liu, H., Ming, L., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08133-7 · Cited by 3 · see citing works

The RNA-binding protein Quaking is essential for cardiac homeostasis and function by regulating Morf4l2 splicing

Kumari, S., Shashi, Singh, S. K., Swain, A., Prakash, S., Chitkara, P., Sharma, R. K., Agarwal, P., Kundu, S., Gaur, A., et al. (2025) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2025.11.002 · Cited by 3 · see citing works

Multidimensional effects of genetic mechanisms in cancer occurrence, development and treatment

Wang, X., Shi, X., Liao, S., Su, T., Gu, Y., Zhang, H., & Li, Z. (2026) · Cancer Genetics · doi:10.1016/j.cancergen.2026.03.006 · Cited by 3 · see citing works

DNA Methylation-Based Diagnosis and Treatment of Breast Cancer

Peng, X., Zheng, J., Liu, T., Zhou, Z., Chen, S., Zhang, D., Zhang, X., & Huang, Y. Y. (2024) · Current Cancer Drug Targets · doi:10.2174/0115680096278978240204162353 · Cited by 3 · see citing works

Chromatin and epigenetic regulation in malignant tumors: A comprehensive review

Zhang, X., Liu, D., Chen, X., Li, T., & Wu, G. (2025) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.70005 · Cited by 3 · see citing works

Long noncoding RNA TUG1 promotes chondrosarcoma progression and M2 polarization

Li, C., Wang, W., Zhong, B., Zhao, L., Li, J., Yu, Y., Zhang, Z., Pu, F., & Liu, J. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101474 · Cited by 3 · see citing works

N-terminal histone acetyltransferase NAA40 modulates osteosarcoma progression by controlling AGR2 expression

Wu, H., Hua, X., Man, Y.-N., Huang, P., Huang, L., & He, M. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151491 · Cited by 3 · see citing works

A predictive model for the transformation from cervical inflammation to cancer based on tumor immune-related factors

Wang, W., Huang, C., Bi, S., Liang, H., Li, S., Lu, T., Liu, B., Tang, Y., & Wang, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1532048 · Cited by 7 · see citing works

DNA Methylation in Ph-Negative Myeloproliferative Neoplasms: Prognostic Role and Therapeutic Implications

Barone, P., Bottaro, A., Leanza, R., Stagno, F., & Allegra, A. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47040227 · Cited by 2 · see citing works

Olfactory receptor OR51B5 suppressed esophageal cancer progression through activates Calcium / N-Ras signaling

Yang, F., Yang, J., Zhu, C., Ding, T., Zhang, X., & Zhang, H. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07769-9 · Cited by 2 · see citing works

Current perspectives and global trends of nanotechnology in advanced breast cancer: a bibliometric and visualized analysis

Huang, H., & Ma, T. (2025) · Discover Oncology · doi:10.1007/s12672-025-03260-1 · Cited by 2 · see citing works

Multidimensional Roles of EZH2 and Its Therapeutic Potential in Cancer TherapyReview Article

Yin, H. Y., Tan, J., He, J., Li, M., & Lin, H. (2025) · Life Conflux · doi:10.71321/q01vae55 · Cited by 2 · see citing works

Suppressing the OTUD7A/KDM5B/GABPA axis enhances the sensitivity of cisplatin through inducing ferroptosis in KRAS-mutant LUAD

Si, R., Shen, Z., Sui, Y., Shi, Y., Zhang, Y., Hu, B., Chen, X., Feng, B., Zhu, M., Sha, X., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08337-x · Cited by 2 · see citing works

Article title: Associations between paraben exposure and breast cancer risk: An integrative epidemiologic, network toxicology, multi-omics and experimental analysis

Ji, L., Yang, G., Ling, M., Xiao, Y., Ou, H., Jiang, Y., Liao, X., Lin, J., & Pan, L. (2026) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2026.119710 · Cited by 2 · see citing works

Identification of immune-mediated aging genes associated with cervical spondylosis through single-cell eQTL Mendelian randomization

Liu, Z., & Xu, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1766215 · Cited by 2 · see citing works

H3K27ac-induced IFITM3 promotes progression of TNBC and resistance to anti-PD-1/PD-L1 therapy via the TNF-α/NF-κB/PD-L1 axis

Li, G., Fu, B., Wang, X., Lin, H., Chen, X., & Zhang, J. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2026.168238 · Cited by 2 · see citing works

The Comprehensive Analysis of Weighted Gene Co-Expression Network Analysis and Machine Learning Revealed Diagnostic Biomarkers for Breast Implant Illness Complicated with Breast Cancer

Huang, Z., Wang, H., Pang, H., Zeng, M., Zhang, G., & Liu, F. (2025) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s507754 · Cited by 2 · see citing works

Phase separation participates in the genetic regulation mechanism of hematopoietic stem cells: potential therapeutic methods

Tang, X., Wang, Y., & Xu, R. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04350-1 · Cited by 2 · see citing works

Decoding the Tumor Microenvironment of Myoepithelial Cells in Triple‐Negative Breast Cancer Through Single‐Cell and Transcriptomic Sequencing and Establishing a Prognostic Model Based on Key Myoepithelial Cell Genes

Yu, X., Tian, Y., Zhang, R., & Yang, Y. (2025) · International Journal of Genomics · doi:10.1155/ijog/6454413 · Cited by 2 · see citing works

TMPO-AS1-hsa-let-7b-5p-EZH2-RNA network predicts poor survival in basal-like breast cancer patients

Vats, P., Baweja, B., Nirmal, S., Singh, A. P., & Nema, R. (2025) · Reports of Practical Oncology & Radiotherapy · doi:10.5603/rpor.105252 · Cited by 2 · see citing works

EZH2 in digestive system cancers: Epigenetic regulation, oncogenic interactions, and therapeutic potential

Hjazi, A. M., Hussn, A., Kareem, A. K., Alshahrani, M. Y., Malathi, H., Nayak, P. P., Chauhan, A. S., & Sharma, J. (2025) · Experimental Cell Research · doi:10.1016/j.yexcr.2025.114648 · Cited by 1 · see citing works

The Role of EZH2 in Initiating Epigenetic Regulation of CRSwNP

Zeng, R., Wang, Y., Song, X., & Wang, J. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s525688 · Cited by 1 · see citing works

NFIC suppressed the epithelial ovarian cancer via modulating the balance of PTEN/TGFβ1/EGR1/BRD4 and SP1/EZH2 induced Inhibition of TBX2/MMPs signaling

Ren, Y., Xu, R., Zhang, D., Su, L., Jin, Y. H., Li, N., & Wang, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-09653-0 · Cited by 1 · see citing works

The Role of Non-Coding Regions in Breast Cancer: From Gene Regulation to Therapeutic Implications

Sabit, H., Sobhy, S., Abdel-Ghany, S. E., Wadan, A.-H. S., Ayodele, O., Albrahim, Y., Banerjee, H. N., El-Hashash, A. H. K., & Arneth, B. (2025) · Pharmaceuticals · doi:10.3390/ph18091370 · Cited by 1 · see citing works

Review Article: EZH2 in Pancreatic Cancer: Epigenetic Driver and Therapeutic Target

Festekdjian, T., & Bonavida, B. (2025) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2025061668 · Cited by 1 · see citing works

Ubiquitin D Promotes Lung Metastasis by Stabilizing MMP3 in Triple-Negative Breast Cancer

Xu, R., Wu, T., Li, H., Ji, S., Zhou, Q., Peng, Y., Zhao, Q., Sun, X., Liu, P., & Du, W. (2025) · Research · doi:10.34133/research.1065 · Cited by 1 · see citing works

Discovery, preclinical safety, and efficacy characterization of SMAC mimetic S-016-1348 as a potential cancer therapeutic

Sinha, A., Nengroo, M. A., Ali, R., Khan, A. A., Dutta, H. S., Singh, A., Saini, K. K., Tripathi, K., Katekar, R. A., Rathaur, S., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2025.12.056 · Cited by 1 · see citing works

Keratin as a Potential Prognostic Biomarker for Breast Cancer Progression: An Evidence-Synthesizing Narrative Review

Khairani, A. F., Alhaq, K. F., Herriyanto, R., Fauzi, M. B., & Alfarafisa, N. M. (2026) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s578887 · Cited by 1 · see citing works

Unveiling the hidden regulators: how post-translational modifications influence the progression and treatment of hepatocellular carcinoma

Qi, S., Yong, X., Ding, Z., Hu, M., Li, Y., Li, L., Hu, H., & Tang, H. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1726574 · Cited by 1 · see citing works

Multivalent Peptide-Guided EZH2 Degradation Sensitizes Immune Checkpoint Therapy in TNBC

Li, M., Zhao, H., Ma, L., Fang, Q., Yang, Y., Zeng, W., Fang, X., & Wang, C. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03182 · Cited by 1 · see citing works

BPGM as an intrinsic brake to constrain metastasis through phospho-epigenetic-mediated carnitine biosynthesis suppression

Wu, M.-Z., Feng, D., Liu, W., Huang, W.-L., Wu, Q., Chou, T., Xiao, W.-H., Yao, Z., Li, Z., Xie, T., et al. (2026) · Neoplasia · doi:10.1016/j.neo.2026.101299 · Cited by 1 · see citing works

Exploring the molecular mechanisms network of breast cancer by multi‐omics analysis

Jiang, W., Zhang, Y., & Wang, Q. (2024) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.14052 · Cited by 1 · see citing works

Abstract 3837: Selective ezh2 functional activation alters the metastatic landscape of triple negative breast cancer

Verma, A., Singh, A., Singh, A. K., Chaturvedi, P., Nengroo, M. A., Saini, K. K., Sinha, A., & Datta, D. B. (2020) · Cancer Research · doi:10.1158/1538-7445.am2020-3837 · Cited by 1 · see citing works

EZH2 T367 phosphorylation activates p38 signaling through lysine methylation to promote breast cancer progression

Gonzalez, M. E., Naimo, G. D., Anwar, T., Paolì, A., Tekula, S. R., Kim, S., Medhora, N., Leflein, S. A., Itkin, J., Trievel, R. C., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104827 · Cited by 17 · see citing works

Abstract 5811: Epigenetic regulation of chromosomal instability in triple-negative breast cancer

Bai, Y., Agustinus, A. S., Meydan, C., McNally, D. R., Yomtoubian, S., Yoffe, L., Melnick, A. M., Bakhoum, S. F. W., & Mittal, V. (2023) · Cancer Research · doi:10.1158/1538-7445.am2023-5811

Abstract OI: Novel non-canonical functions of EZH2 in triple negative breast cancer

Kleer, C. G. (2020) · Cancer Research · doi:10.1158/1538-7445.sabcs19-oi · Cited by 1 · see citing works

Abstract 1437: Enhancer of zeste homologue 2 (EZH2) knockdown reveals molecular drivers of EMT and metastasis in triple negative breast cancer (TNBC)

Pietrzak, M., Rima, X. P., Sarathy, G., Dhekne, S., Rizzotto, L., Palmieri, D., Gupta, S. K., Stover, D. G., Reátegui, E., Rolfo, C. D., et al. (2025) · Cancer Research · doi:10.1158/1538-7445.am2025-1437